The Peptide Dam May Be Breaking — What RFK Jr. Actually Said on Rogan

If you spent any time in the longevity medicine world over the past two years, you already know the frustration. Peptides that physicians had been prescribing — compounds like BPC-157, Thymosin Alpha-1, and AOD-9604 — got quietly swept off the compounding pharmacy table starting in late 2023, when the FDA moved nearly 20 peptides to Category 2 of the 503A Bulk Drug Substances list. No safety signals. No randomized trial data documenting harm. Just gone.

Last Friday, something shifted. Robert F. Kennedy Jr., appearing on Joe Rogan’s podcast (JRE #2461, released February 27, 2026), made a statement that’s been ricocheting through the longevity and compounding pharmacy communities ever since: roughly 14 of those 19 restricted peptides are expected to move back to Category 1 — and it could happen within weeks.

This is worth unpacking carefully — because the clinical and regulatory implications are significant, and some important caveats get lost in the excitement.

First, a Quick Reminder: How We Got Here

In September 2023, the FDA added approximately 19 peptides to the 503A Category 2 list — substances deemed to present “significant safety risks” when compounded. Category 2 designation effectively kills compounding pharmacy access. Under federal law, the FDA is only supposed to move a compound to Category 2 based on a legitimate safety signal, not on questions of efficacy or lack of FDA approval. Many in the field argued the agency violated its own legal framework.

The affected peptides included names that longevity clinicians had been using with growing frequency: BPC-157, Thymosin Alpha-1, Thymosin Beta-4 (TB-500), AOD-9604, Selank, Semax, KPV, MOTS-C, GHK-Cu, and others. The compounding market dried up overnight for these compounds. Patients and practitioners didn’t disappear, though — they shifted. Some moved to overseas suppliers. Others turned to “research use only” vendors with no pharmaceutical oversight. As Kennedy himself acknowledged on the podcast: “We created the gray market.”

Compounding pharmacies fought back legally, arguing the FDA had skipped procedurally required steps. That litigation forced the agency to convene public advisory panels — which, at the time, voted to uphold most of the restrictions. Meanwhile, under Kennedy’s leadership at HHS, the FDA removed several members from the compounding advisory panel, signaling that the political winds were shifting.

What RFK Jr. Actually Said

Kennedy’s comments on JRE #2461 were direct. He characterized the FDA’s original move as illegal — arguing the agency had no qualifying safety basis to act. He acknowledged that by banning compounded access without a legitimate safety rationale, the FDA had inadvertently created the gray market it was supposedly trying to prevent. He then stated plainly that the administration intends to reverse the restriction for approximately 14 of the 19 peptides, within the coming weeks.

If the reversal holds, those 14 peptides would return to Category 1 status — meaning licensed compounding pharmacies could legally prepare them again for patients with valid prescriptions from a licensed healthcare provider.

The five peptides most likely to remain restricted are those with the weakest human safety and efficacy data, or where specific concerns have been raised. Melanotan II (due to melanoma risk concerns) and several growth hormone secretagogues — GHRP-2, Ipamorelin, CJC-1295 — have been mentioned as likely candidates to stay in Category 2.

What This Means Clinically

For practicing physicians, especially those working in longevity, regenerative medicine, and integrative care, this is a meaningful shift — if it materializes. Here’s the practical breakdown:

Compounded access ≠ FDA approval. This cannot be overstated. A Category 1 reclassification means licensed 503A pharmacies can compound these peptides for individual patients. It does not mean the FDA has endorsed them as safe or effective for any indication. The evidentiary base for most of these compounds remains thin by conventional clinical standards — largely animal data, small observational studies, and the kind of mechanistic research that is compelling in theory but not yet validated in large human trials.

Prescribing requires a prescription. Patients cannot simply walk into a compounding pharmacy. These compounds require physician authorization, which means the physician is taking on clinical and medicolegal responsibility. That’s actually the appropriate model — it routes access through medical oversight rather than through gray market channels — but physicians should document their clinical rationale carefully.

Quality control returns. This is arguably the most underappreciated benefit of legal compounding access. USP 797/795-compliant pharmacies operate under sterility and purity standards that gray market vendors simply don’t. A December 2025 investigation documented widespread availability of unapproved peptides on major retail platforms with no guarantees of purity, potency, or sterility. Legal compounding routes that risk back into a regulated environment.

The evidence gap doesn’t close. Access returning doesn’t change the fact that rigorous randomized controlled trial data in humans remains sparse for most of these compounds. BPC-157 has compelling animal data for gut healing, tendon repair, and neuroprotection. Thymosin Alpha-1 has the most robust human data, with established use in immune modulation. But for most others, we’re still operating largely on mechanistic plausibility and clinical anecdote. Physicians should communicate this clearly to patients.

The Compounds Most Likely to Return

Based on available analysis, the following peptides are among those expected to regain Category 1 status: BPC-157, Thymosin Alpha-1, Thymosin Beta-4 (TB-500), AOD-9604, Selank, Semax, KPV, MOTS-C, and GHK-Cu (copper peptide). These represent a range of mechanisms — gut/tissue repair, immune modulation, cognitive support, metabolic function, and skin/wound healing.

Each warrants its own clinical discussion, and we’ll be doing deeper dives on several of these in upcoming issues. The key point for now: these are the compounds your patients have been asking about, many of them have been sourcing through unregulated channels, and if Kennedy’s announcement holds, you’ll soon have a legal pathway to prescribe through licensed pharmacies again.

The Bottom Line for Longevity Practitioners

If the announced reclassification moves forward, it represents the most significant regulatory opening for peptide prescribing in years — and it shifts the conversation from gray market harm reduction to legitimate clinical practice. That’s a meaningful change. Physicians will have a legal framework to prescribe through quality-controlled pharmacies, document their rationale, and monitor outcomes.

It also creates an obligation. When access expands, so does clinical responsibility. Patients who’ve been sourcing peptides from overseas suppliers or research vendors deserve a real medical evaluation — not just a rubber-stamp prescription. The compounds returning to compounding aren’t fully validated therapeutics. They’re promising agents that require thoughtful patient selection, appropriate counseling on evidence quality, and ongoing monitoring.

The gray market that grew up around these peptides was a predictable consequence of cutting off legitimate access without a real safety justification. If Kennedy follows through, we have a chance to bring that market back under medical oversight — which is where it should have been all along.

We’ll be tracking the formal FDA update closely and will publish a full clinical brief when the 503A list is officially revised. In the meantime, the full JRE #2461 episode is worth watching for context — whatever you think of the venue, Kennedy’s comments on the regulatory history are specific and substantive.

This Substack is written by a licensed physician for educational and informational purposes only. The content published here — including discussion of peptides, off-label therapeutics, emerging research, and regulatory developments — does not constitute medical advice, diagnosis, or treatment.

Nothing in this publication should be interpreted as a recommendation to use, obtain, or discontinue any medication, supplement, or therapeutic intervention. Many compounds discussed on this Substack are investigational, lack FDA approval for the indications described, or are currently in a regulatory gray area. Evidence quality varies widely across topics covered; where human clinical trial data is limited or absent, this will be noted.

Reading this publication does not establish a physician-patient relationship between the author and the reader. Individual medical decisions should be made in consultation with a qualified healthcare provider who has access to your full medical history, current medications, and relevant labs.

Regulatory status, evidence bases, and clinical guidelines change. Information presented here reflects the author’s understanding at the time of publication and may not reflect subsequent developments.

The author may discuss compounds or interventions that are not legal to prescribe, obtain, or use in all jurisdictions. Readers are responsible for understanding the laws applicable in their own location.